{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:55:40Z","timestamp":1787169340823,"version":"build-2736575974"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>PReferentially Expressed Antigen in MElanoma (PRAME) was introduced as an ancillary tool for confirming the diagnosis of cutaneous melanoma, including the acral lentiginous melanoma (ALM). However, its standardized cut-off values and prognostic performance remain inconclusive. This study assessed the diagnostic performance of PRAME immunohistochemistry (IHC) in ALM across different thresholds and explored its prognostic associations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This retrospective cohort study reviewed 90 acral melanocytic lesions, including 60 cases of acral benign nevi and 30 cases of primary ALM. PRAME immunohistochemistry was performed on the biopsy specimens. Sensitivity and specificity were calculated at varying cut-offs. The optimal threshold was applied to link PRAME expression with the outcome and features of ALM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A PRAME staining threshold of 50% (score \u22653) provided the optimum cut-off for differentiating ALM, with a high specificity of 98.3% and sensitivity of 53.3%. Positive PRAME was significantly associated with higher TNM stages (ordinal odds ratio [95% confidence interval], 13.11 [2.55\u201367.27]) and higher rates of recurrence (hazard ratio, 6.62 [1.42\u201330.94]) but not with any unfavorable histopathological features or mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>PRAME can be used as an adjunctive diagnostic tool to differentiate malignant from benign acral melanocytic lesions. It may serve as a prognostic marker for poor ALM outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/dad.0000000000003305","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T14:03:40Z","timestamp":1779890620000},"page":"684-690","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Diagnostic and Prognostic Values of PRAME Immunohistochemistry in Acral Lentiginous Melanoma"],"prefix":"10.1097","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8552-9277","authenticated-orcid":false,"given":"Korn","family":"Triyangkulsri","sequence":"first","affiliation":[{"name":"Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namthong","family":"Wittayabusarakam","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supachak","family":"Smitthisakda","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawara","family":"Sakpuwadol","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunlawat","family":"Thadanipon","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand;"},{"name":"Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bantita","family":"Phruttinarakorn","sequence":"additional","affiliation":[{"name":"Department of Pathology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8268-8790","authenticated-orcid":false,"given":"Suthinee","family":"Rutnin","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"R1-20260819","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1097\/PAS.0000000000001134","article-title":"PRAME expression in melanocytic tumors","volume":"42","author":"Lezcano","year":"2018","journal-title":"Am J Surg Pathol."},{"key":"R2-20260819","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1074-7613(00)80426-4","article-title":"Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor","volume":"6","author":"Ikeda","year":"1997","journal-title":"Immunity"},{"key":"R3-20260819","doi-asserted-by":"crossref","first-page":"15881","DOI":"10.3390\/ijms242115881","article-title":"Cutaneous melanoma: a review of multifactorial pathogenesis, immunohistochemistry, and emerging biomarkers for early detection and management","volume":"24","author":"Gosman","year":"2023","journal-title":"Int J Mol Sci."},{"key":"R4-20260819","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.3390\/cells13201740","article-title":"The utilization of PRAME in the diagnosis, prognosis, and treatment of melanoma","volume":"13","author":"Blount","year":"2024","journal-title":"Cells"},{"key":"R5-20260819","doi-asserted-by":"crossref","first-page":"8828579","DOI":"10.1155\/2020\/8828579","article-title":"Clinicopathological and prognostic significance of PRAME overexpression in human cancer: a meta-analysis","volume":"2020","author":"Li","year":"2020","journal-title":"Biomed Res Int."},{"key":"R6-20260819","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/DAD.0000000000002440","article-title":"Immunohistochemistry for PRAME in dermatopathology","volume":"45","author":"Lezcano","year":"2023","journal-title":"Am J Dermatopathol."},{"key":"R7-20260819","first-page":"820","article-title":"Clinicopathological features and prognostic factors of malignant melanoma: a retrospective analysis of Thai patients in ramathibodi Hospital","volume":"98","author":"Ingkaninanda","year":"2015","journal-title":"J Med Assoc Thai."},{"key":"R8-20260819","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10147-007-0751-1","article-title":"Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update","volume":"13","author":"Ishihara","year":"2008","journal-title":"Int J Clin Oncol."},{"key":"R9-20260819","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/PAS.0000000000001492","article-title":"Comparison of immunohistochemistry for PRAME with cytogenetic test results in the evaluation of challenging melanocytic tumors","volume":"44","author":"Lezcano","year":"2020","journal-title":"Am J Surg Pathol."},{"key":"R10-20260819","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1097\/DAD.0000000000002555","article-title":"Comparison of melanocyte-associated immunohistochemical markers in acral lentiginous melanoma and acral benign nevi","volume":"45","author":"Kim","year":"2023","journal-title":"Am J Dermatopathol."},{"key":"R11-20260819","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/DAD.0000000000002932","article-title":"Clinicopathologic features of PRAME-positive common melanocytic nevi: a case-control Study","volume":"47","author":"Knittel","year":"2025","journal-title":"Am J Dermatopathol."},{"key":"R12-20260819","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1097\/DAD.0000000000003104","article-title":"PRAME expression in recurrent\/persistent melanocytic nevi","volume":"47","author":"Kucharik","year":"2025","journal-title":"Am J Dermatopathol."},{"key":"R13-20260819","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/cup.14130","article-title":"Preferentially expressed antigen in melanoma and p16 expression in acral melanocytic neoplasms","volume":"49","author":"McBride","year":"2022","journal-title":"J Cutan Pathol."},{"key":"R14-20260819","first-page":"472","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin."},{"key":"R15-20260819","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.humpath.2021.11.002","article-title":"Preferentially expressed antigen in melanoma immunohistochemistry as an adjunct for differential diagnosis in acral lentiginous melanoma and acral nevi","volume":"120","author":"Hu","year":"2022","journal-title":"Hum Pathol."},{"key":"R16-20260819","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/PAS.0000000000001878","article-title":"Comparative analysis of PRAME expression in 127 acral and nail melanocytic lesions","volume":"46","author":"Santandrea","year":"2022","journal-title":"Am J Surg Pathol."},{"key":"R17-20260819","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/cup.14226","article-title":"PRAME expression in melanocytic lesions of the nail","volume":"49","author":"Parra","year":"2022","journal-title":"J Cutan Pathol."},{"key":"R18-20260819","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1136\/jcp-2022-208697","article-title":"Analysis of PRAME immunocytochemistry in 109 acral malignant melanoma in situ","volume":"77","author":"Miao","year":"2024","journal-title":"J Clin Pathol."},{"key":"R19-20260819","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1097\/DAD.0000000000001885","article-title":"Preferentially expressed antigen in melanoma immunostaining in a series of melanocytic neoplasms","volume":"43","author":"Googe","year":"2021","journal-title":"Am J Dermatopathol."},{"key":"R20-20260819","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.3390\/cancers13153864","article-title":"Diffuse PRAME expression is highly specific for thin melanomas in the distinction from severely dysplastic nevi but does not distinguish metastasizing from non-metastasizing thin melanomas","volume":"13","author":"Gassenmaier","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R21-20260819","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/his.14904","article-title":"Diagnostic test accuracy meta-analysis of PRAME in distinguishing primary cutaneous melanomas from benign melanocytic lesions","volume":"83","author":"Kunc","year":"2023","journal-title":"Histopathology"},{"key":"R22-20260819","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/DAD.0000000000002863","article-title":"The utility of PRAME and Ki-67 as prognostic markers for cutaneous melanoma","volume":"47","author":"Asato","year":"2025","journal-title":"Am J Dermatopathol."},{"key":"R23-20260819","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/cup.14495","article-title":"PRAME expression in cutaneous melanoma does not correlate with disease-specific survival","volume":"50","author":"Parra","year":"2023","journal-title":"J Cutan Pathol."},{"key":"R24-20260819","doi-asserted-by":"crossref","first-page":"154543","DOI":"10.1016\/j.prp.2023.154543","article-title":"Immunohistochemical expression of PRAME is a marker of poor prognosis in uveal melanoma: a clinico-pathologic and immunohistochemical study on a series of 85 cases","volume":"247","author":"Broggi","year":"2023","journal-title":"Pathol Res Pract."},{"key":"R25-20260819","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/PAS.0000000000001393","article-title":"Immunohistochemistry for PRAME in the distinction of nodal Nevi from metastatic Melanoma","volume":"44","author":"Lezcano","year":"2020","journal-title":"Am J Surg Pathol."}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/DAD.0000000000003305","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:00:41Z","timestamp":1787166041000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/DAD.0000000000003305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/dad.0000000000003305","relation":{},"ISSN":["0193-1091","1533-0311"],"issn-type":[{"value":"0193-1091","type":"print"},{"value":"1533-0311","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]}}}